Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00968110 · ClinicalTrials.gov registry record · Early Phase 1
Xolair Treatment for Milk Allergic Children
A Early Phase 1 study, sponsored by Boston Children's Hospital.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
NCT00968110 is a Early Phase 1 study that has completed, run by Boston Children's Hospital. The registered enrollment target is 10 participants.
The verdict
NCT00968110, a Early Phase 1 study, has completed, sponsored by Boston Children's Hospital.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This is a pilot feasibility study, using Xolair pretreatment for oral milk desensitization. The major assessment will be safety, and the investigators will evaluate for any type of reaction, including allergic reactions that occur during the course of the study.
Interventions
- DRUG omalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2009-03 |
| Est. Completion | 2017-04 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00968110
The ClinicalTrials.gov registry entry for NCT00968110 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Children's Hospital, which has 462 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which omalizumab is the first listed.
NCT00968110 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00968110 about?
NCT00968110 is a clinical study titled "Xolair Treatment for Milk Allergic Children". This is a pilot feasibility study, using Xolair pretreatment for oral milk desensitization. The major assessment will be safety, and the investigators will evaluate for any type of reaction, including allergic reactions that occur during the course of the study.
What is the current status of trial NCT00968110?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2009-03. Estimated completion is 2017-04.
What interventions are being tested in trial NCT00968110?
The interventions under investigation include: omalizumab (DRUG).
Who is sponsoring clinical trial NCT00968110?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.